Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoRecormon in chronic renal anemia (CREATE)
NCT00321919Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2000
- Primary completion
- Oct 2004
- Modality
- Erythropoietins, Colony Stimulating Factors
- Countries
- 22
01
Overview
Phase 3, randomised, open-label trial of epoetin beta in anemia of chronic kidney disease (2 arms), sponsored by Roche. Primary endpoint: Median Time to First Cardiovascular Event at 4 years. Started Jul 2000; status: completed.
02
Drugs
epoetin beta
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on NCT00321919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00321919.